ECM
SER icon

ExodusPoint Capital Management’s Serina Therapeutics SER Stock Holding History

ExodusPoint Capital Management’s Portfolio SER Stock Details SER Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-525
Closed -$75K – 1367
2019
Q1 		$75K Buy
+525
New +$76.8K 0.01% 625

Other funds holding SER

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

ExodusPoint Capital Management's SER Position: Q2 2019 in Review

ExodusPoint Capital Management sold out of Serina Therapeutics (SER) in Q2 2019, closing a stake of 525 shares — an estimated $75K sold.

ExodusPoint Capital Management first reported a position in SER in Q1 2019 and held it in 1 quarter. The position peaked at $75K in Q1 2019. 51 funds tracked by Wall St. Rank hold SER as of Q2 2019.

  • ExodusPoint Capital Management reported no remaining Serina Therapeutics position as of Q2 2019 after selling out during the quarter.
  • ExodusPoint Capital Management sold 525 Serina Therapeutics shares in Q2 2019, an estimated $75K.
  • ExodusPoint Capital Management first reported a position in Serina Therapeutics in Q1 2019 and held it in 1 quarter.
  • ExodusPoint Capital Management's Serina Therapeutics position peaked at $75K in Q1 2019.
  • 51 funds tracked by Wall St. Rank held Serina Therapeutics as of Q2 2019.

Based on ExodusPoint Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.